Stocks Health care CVSI
OTC · Health careCV Sciences, Inc. (CVSI)
CV Sciences, Inc. brought in $12.7M of revenue over the twelve months to June 30, 2026, down 14.9% from a year earlier. It posted a net loss of $2M. In fiscal 2025 capital spending exceeded operating cash flow by $516K. At June 30, 2026 it held $266K in cash against $18K of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Watch CVSI in 60 secondsWhat CV Sciences, Inc. does
CV Sciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker CVSI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $13.8M | -$958K | -$0.01 | -$516K |
| 2024 | $15.7M | -$2.4M | -$0.01 | -$879K |
| 2023 | $16M | $3.1M | $0.02 | $2.3M |
| 2022 | $16.2M | -$8.2M | -$0.07 | -$1.9M |
| 2021 | $20M | -$15.6M | -$0.14 | -$7.5M |
| 2020 | $24.4M | -$22.3M | -$0.22 | -$8.4M |
Full financial statements: income, balance sheet and cash flow
Where CVSI ranks in Health care
Latest SEC filings
What CV Sciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 9, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 18% to $3M versus the same quarter last year; diluted EPS $0.00 versus $0.00.
- August 13, 2026
- June 4, 2026
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 11% to $3.2M versus the same quarter last year; diluted EPS $0.00 versus $0.00.
- May 14, 2026
- April 15, 2026Proxy statement DEF 14A
- April 10, 2026
- March 26, 2026Annual report 10-K · period to December 31, 2025Revenue fell 12% to $13.8M versus the prior year; diluted EPS -$0.01 versus -$0.01.
- March 26, 2026
Insider trades
What the people running CV Sciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $114.8K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 7, 2026 | Cheever Charlie E III10% owner | Bought | 94,854 | $1.9K |
| August 4, 2026 | Cheever Charlie E III10% owner | Bought | 108,000 | $2.2K |
| July 31, 2026 | Cheever Charlie E III10% owner | Bought | 1,730,000 | $34.6K |
| July 29, 2026 | Cheever Charlie E III10% owner | Bought | 60,000 | $1.2K |
| July 28, 2026 | Cheever Charlie E III10% owner | Bought | 1,830,000 | $36.6K |
| July 24, 2026 | Cheever Charlie E III10% owner | Bought | 470,075 | $9.4K |
| July 22, 2026 | Cheever Charlie E III10% owner | Bought | 272,500 | $5.5K |
| July 21, 2026 | Cheever Charlie E III10% owner | Bought | 335,000 | $6.7K |
| July 17, 2026 | Cheever Charlie E III10% owner | Bought | 749,000 | $15K |
| July 16, 2026 | Cheever Charlie E III10% owner | Bought | 91,387 | $1.8K |
Who owns CVSI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Cheever Charlie E III13G, passive | 13.1% | September 9, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 26,648,711 shares in total, about $346.4K at the last price.
| Holder | Shares |
|---|---|
| Cheever Charlie E III10% owner | 26,648,711 |
Questions about CVSI
What does CV Sciences, Inc. do?
CV Sciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker CVSI.
Is CV Sciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $2M on revenue of $12.7M.
How much revenue does CV Sciences, Inc. make?
Over the twelve months to June 30, 2026 CV Sciences, Inc. reported revenue of $12.7M. That is 14.9% less than a year earlier.
When did CV Sciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from September 9, 2026.
Similar companies
Compare CVSI with
Follow CVSI
Get an email when CV Sciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CVSI: get an email when it filesWhere the numbers come from
Financial figures are the values CV Sciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.